Pulmonary autograft for mitral valve replacement: Making a simple procedure complex?  by Al-Ebrahim, Khaled E.
Letters to the EditorWith regard to the possible resistance
by surgeons to adopt these interven-
tions, we think the availability of com-
pelling evidence in support of these
interventions to prevent lung injury
will eliminate any practical concerns.
Dr Macedo and colleagues refer to
a trial that will assess the effect of lung
perfusion/ventilation during CPB. We
look forward to their results, which
will hopefully add further knowledge
to face the continued ch allenge of
lung injury during cardiac surgery.
Hajime Imura, MDa
Gianni D. Angelini, FRCSb
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I read with interest the article by
Kumar and colleagues1 about the useThe Journalof pulmonary autografts for mitral
valve replacement. I agree with the au-
thors that cardiac surgeons working in
Third World countries are faced with
a major problem in the management
of large numbers of patients with val-
vular disease. Most of those patients
are of low socioeconomic and educa-
tional class, living in remote villages
and mountains. There is no family
practice or general practitioner system
to provide early diagnosis and referral,
postoperative follow-up, and anticoa-
gulation control. Patients usually pres-
ent late with advanced disease that
makes repair impossible. The magni-
tude of the problem is escalated in chil-
dren and women of childbearing age
because we have no ideal valve
substitute.
The pulmonary autograft concept is
attractive but still has its drawbacks
and complications. The procedure is
complex and technically demanding,
requiring at least double the usual
crossclamp and bypass times. The
procedure is not free of charge be-
cause there is a price for the homo-
grafts or preparation of the
autografts, plus the added cost of
complications. The mortality of ap-
proximately 15% reported by the au-
thors is still high compared with
single mitral valve replacement. Kab-
bani and colleagues2 reported 5%
early mortality and 6% late mortality,
but as they stated, it is ‘‘clearly re-
lated to the procedure,’’ which entails
higher overall mortality. The issue of
converting a single-valve into a dou-
ble-valve disease is irritating because
we have to expect long-term sequelae
of pulmonary and mitral valve fail-
ures. The main concern with pulmo-
nary autografts or homografts is
early calcification. The removal of
calcified grafts, as experienced in aor-
tic homografts, is usually disastrous
and has a high complication rate, in-
cluding left ventricular rupture. The
same complications are associated
with the use of aortic or mitral homo-
grafts for mitral valve replacement.
All of these autografts and homo-of Thoracic and Cardiovascular Surgegrafts have to compete with the stan-
dard stented bioprostheses, which are
improving and technically easier to
insert, and require no anticoagulation.
At the present time, bioprosthetic
valves remain the standard in these
patients, and manufacturers have
shown us better preservation and lon-
ger durability.3
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doi:10.1016/j.jtcvs.2009.08.049Reply to the Editor:
We are thankful to Dr Khaled E. Al-
Ebrahim for his comments and cri-
tique. These were the same arguments
raised when the Ross procedure for
aortic valve replacement was first
reported by Donald Ross in 1967.
The patients undergoing operation
are young and clearly unsuitable for
tissue valves. The surgery is indeed
complex but provides superior hemo-
dynamic results with a higher valve
area. In addition, these patients only
require an echocardiogram at yearly
intervals, receive no medication 1
year after surgery, and do not require
blood tests. The most important
advantage is that it is a living valve,
and we now have more than a 15-
year follow-up of our own results for
the Ross (aortic valve replacement)
procedure. There has been no reopera-
tion in the adults with a pulmonary
homograft.
We believe these early results will
translate into superior outcomes inry c Volume 139, Number 1 237
